• 1
    Engman MF. Burning tongue. Arch Dermatol Syph 1920; 1: 137138.
  • 2
    Ito M, Kimura H, Yoshida K et al. Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region. Clin Neuropharmacol 2010; 33: 7983.
  • 3
    American Psychiatric Association. Diagnosis and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.
  • 4
    Hirata Y, Matsuda H, Nemoto K et al. Voxel-based morphometry to discriminate early Alzheimer's disease from controls. Neurosci Lett 2005; 382: 269274.
  • 5
    Kashima K, Takamori K, Igawa K, Nagata J, Yoshioka I, Sakada S. The efficacy of milnacipran hydrochloride for glossodynia. Shinyaku to Rinsho 2010; 59: 21502157. (in Japanese with English abstract).
  • 6
    Ikawa M, Yamada K, Ikeuchi S. Efficacy of amitriptyline for treatment of somatoform pain disorder in the orofacial region: a case series. J Orofac Pain 2006; 3: 234240.
  • 7
    Yamazaki Y, Hata H, Kitamori S et al. An open-label, noncomparative, dose escalation pilot study of the effect of paroxetine in treatment of burning mouth syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 107: e6e11.
  • 8
    Toyofuku A. Efficacy of milnacipran for glossodynia patients. Int J Psychiatry Clin Pract 2003; 7: 2324.
  • 9
    Kato Y, Sato T, Katagiri A et al. Milnacipran dose-effect study in patients with burning mouth syndrome. Clin Neuropharmacol 2011; 34: 166169.
  • 10
    Ito T, Kudo Y, Kimura M, Hada M. A case of chronic pain disorder responding to SNRI (milnacipran). Rinsho Seisin Igaku 2003; 32: 563568. (in Japanese).
  • 11
    Mico JA, Ardid D, Berrocoso E, Eschalier A. Antidepressants and pain. Trends Pharmacol Sci 2006; 27: 348354.
  • 12
    Kimura H, Yoshida K, Ito M et al. Plasma levels of milnacipran and its effectiveness for the treatment of chronic pain in the orofacial region. Hum Psychopharmacol 2012; 27: 323328.
  • 13
    Otani K, Miura Y, Suzuki A, Kinoshita O. Effectiveness and safety of milnacipran treatment for a patient with delusion disorder, somatic type taking multiple medications for concomitant physical diseases. Clin Neuropharmacol 2010; 33: 212213.
  • 14
    Wijkstra J, Burger H, van den Broek WW et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatr Scand 2010; 121: 190200.
  • 15
    Navarro A, Saldana MT, Perez C, Torrades S, Rejas J. Patient-reported outcomes in subjects with neuropathic pain receiving pregabalin: evidence from medical practice in primary care settings. Pain Med 2010; 11: 719731.
  • 16
    Lopez V, Alonso V, Marti N, Calduch L, Jorda E. Marked response of burning mouth syndrome to pregabalin treatment. Clin Exp Dematol 2009; 34: e449e450.